BI-C

N/A

Report date: 2025/09/24 15:38:42
NME

Base Information

Drug NameBI-C
Drug Alias Namecomplement 3 inhibitor (Boehringer Ingelheim)
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionComplement C3 inhibitors
TargetsComplement C3
Therapy Area/IndicationsGeographic AtrophyRetinal Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBoehringer Ingelheim International Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesBoehringer Ingelheim International Gmbh
Inactive CompaniesN/A
Active IndicationsGeographic AtrophyRetinal Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A